Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-03-14 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Update on US review of Fasenra in nasal polyps
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 5901E' and is dated 14 March 2022, indicating it is a regulatory announcement disseminated via the RNS system of the London Stock Exchange. The content details an update regarding the US FDA's Complete Response Letter (CRL) for a supplemental Biologics License Application (sBLA) for the drug Fasenra. This is a specific, material event disclosure concerning regulatory interaction and clinical trial data updates, rather than a comprehensive financial report (like 10-K or IR) or a general management/board change. Since it is a specific regulatory update disseminated through the RNS system and does not fit into the more specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Earnings Release (ER), the most appropriate classification is the general regulatory announcement category, RNS.
2022-03-14 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2022-03-09 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification released via RNS (Regulatory News Service) concerning a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR). Specifically, it details the vesting of shares under a Deferred Bonus Plan for the CEO, Pascal Soriot, and includes the required disclosure tables mandated by market abuse regulations. This type of insider transaction reporting, especially when filed through a primary information provider like RNS, falls under the category of Director's Dealing (DIRS). Although it is a regulatory filing, DIRS is a more specific and appropriate classification than the general RNS fallback.
2022-03-09 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2022-03-07 English
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is identified by the RNS Number header and explicitly states it concerns 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)' regarding the granting of share awards to executives (Pascal Soriot and Aradhana Sarin). This type of filing, detailing personal share transactions by company directors and executives, directly matches the definition for Director's Dealing (DIRS). Although it references the Annual Report for performance details, the core content is the insider transaction disclosure, which is a specific regulatory requirement.
2022-03-07 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2022-03-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.